Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Multiple Doses of BI 730357 on the Single Dose Pharmacokinetics of Caffeine, Warfarin, Omeprazole and Midazolam Administered Orally as a Cocktail in Healthy Subjects (an Open-label, Two-period Fixed Sequence Design Trial)

Next Previous
X
Search
Trial Profile

The Effect of Multiple Doses of BI 730357 on the Single Dose Pharmacokinetics of Caffeine, Warfarin, Omeprazole and Midazolam Administered Orally as a Cocktail in Healthy Subjects (an Open-label, Two-period Fixed Sequence Design Trial)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 730357 (Primary) ; Caffeine; Midazolam; Omeprazole; Warfarin
  • Indications Ankylosing spondylitis; Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 18 Mar 2021 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2021 Planned End Date changed from 8 Mar 2021 to 15 Mar 2021.
    • 10 Mar 2021 Planned primary completion date changed from 8 Mar 2021 to 15 Mar 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top